FIG 2.

Characterization of tumor-associated antigen cytotoxic T cell (TAA-T) products. (A) Flow cytometry demonstrates a variable phenotype of polyclonal, polyfunctional T-cell products in patients in the Responding group. (B) Patients in the Nonresponding group showed a comparatively lower percentage of CD8⁺CD3⁺ cells and CD16⁺CD56⁺CD3⁺ cells with high percentages of CD4⁺CD3⁺ cells. (C) Luminex assay to measure cytokine secretion by TAA-T products. Interferon gamma (IFNγ), tumor necrosis factor α (TNFα), and MIP1b were the cytokines most commonly detected in response to antigen stimulation. (D) Product TAA specificity as measured by IFNγ enzyme-linked immunospot assay. Number on the x-axis corresponds to patient number and, when applicable, multiple products are numbered accordingly (eg, T4, T4.2, and T4.3 are the first, second, and third products administered to P4). TAA-T products demonstrated variable specificity to the targeted antigens. GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; MIP-1b, macrophage inflammatory protein 1β; PRAME, preferentially expressed antigen of melanoma; WT1, Wilms tumor 1.